Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  recombinant interleukin-6
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 29 for your search:
Start Over
Phase I/II Study of IL-6 for Relapsed or Refractory AML (Summary Last Modified 03/97)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: RPMI-DS-9422, NCI-T93-0177D, T93-0177
Phase I/II Study of Escalating IL-6 with GM-CSF/EPO for Myelodysplastic Syndrome (Summary Last Modified 03/97)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RPMI-DS-9429, NCI-T94-0072D, T94-0072
Phase II Pilot Study of MDR-1 Retrovirus-Transduced Peripheral Blood Stem Cells for Chemoprotection During Therapy for Advanced Breast Cancer (Summary Last Modified 08/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: NCI
Protocol IDs: MDA-DM-94028, NCI-T95-0064D, T95-0064
Phase II Pilot Study of High-Dose Ifosfamide/Carboplatin/Etoposide (ICE) Followed by Transplantation with neo-r-Transduced Autologous Bone Marrow and PBSC for Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: NCI
Protocol IDs: NCI-92-C-0161I, NCI-MB-294, NCI-T92-0018N, T92-0018
Phase II Study of IL-6 Administered by 120-Hour Continuous Intravenous Infusion in Patients with Advanced Renal Cell Carcinoma (Summary Last Modified 08/93)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: IDB-IL-6/RENAL, NCI-T93-0038N, T93-0038
Phase II Study of IL-6 Administered by 1-Hour Intravenous Infusion in Patients with Metastatic or Locally Advanced Melanoma (Summary Last Modified 10/93)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: IDB-IL-6/MELANOMA, NCI-T93-0049N, T93-0049
Phase II Study of IL-6 for Metastatic Renal Cell Cancer (Summary Last Modified 11/94)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: CCF-RPC-3272F, NCI-B93-0005, B93-0005
Phase II Study of IL-6 in Patients with Smoldering Relapse of AML (Summary Last Modified 12/93)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 17 and over
Sponsor: NCI
Protocol IDs: MDA-DM-93081, NCI-T93-0130C, T93-0130
Phase I Study of IL-3/IL-6 in Patients with Myelodysplastic Syndrome (Summary Last Modified 07/94)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: DFCI-93079, NCI-T93-0001D, T93-0001
Phase I Study of IL-6/GM-CSF Following High-Dose CBDCA in Patients with Recurrent Ovarian Cancer (Summary Last Modified 06/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-94-C-0023C, NCI-MB-320, NCI-T93-0042N, T93-0042
Phase IA/IB Study of GM-CSF/IL-6 for Advanced Renal Cell Carcinoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CCF-RPC-2520E, NCI-T93-0158C, T93-0158
Phase I Study of IL-6/G-CSF in Association with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Advanced Breast Cancer (Summary Last Modified 01/98)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: DMS-9224, NCI-T93-0026D, T93-0026
Phase I Pilot Study of MDR-1 Retrovirus Transduced Bone Marrow for Chemoprotection During TAX Therapy for Ovarian Cancer (Summary Last Modified 06/95)
Phase: Phase I
Type: Supportive care, Treatment
Status: Closed
Age: 18 to 60
Sponsor: NCI
Protocol IDs: MDA-DM-93012, NCI-T93-0160D, T93-0160
Phase I Study of IL-6 in Patients with Advanced Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-91-C-199B, NCI-T91-0150N, T91-0150
Phase I Study to Evaluate the Safety, Tolerance, and Biological Effects of IL-6 in Patients with Myelodysplastic Syndrome (Summary Last Modified 04/92)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 16-75
Sponsor:
Protocol IDs: WPCI-9175, NCI-V91-0215
Phase IA/B Trial of IL-6 in Patients with Advanced Malignancy (Summary Last Modified 08/92)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: CCF-RPC-3272E, NCI-B91-0019, B91-0019
Phase I Study of IL-6 in Patients with Advanced Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-92-C-0143, NCI-T92-0040N, T92-0040
Phase I Study of IL-6 Administered Intravenously Over One Hour in Patients with Solid Tumors (Summary Last Modified 03/93)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: IDB-IL-6, NCI-T92-0049O, T92-0049
Phase I Study of IL-6 as a 120-Hour Continuous Infusion in Patients with Locally Advanced or Metastatic Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: IDB-IL-6/120HR, NCI-T92-0062O, T92-0062
Phase I Pilot Study of TAX/CBDCA/G-CSF with and without IL-6 for Untreated Suboptimal Stage III/IV Ovarian Epithelial or Primary Peritoneal Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-9202
Start Over